Show simple item record

Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression

dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorGholami, Mohammad Hossein
dc.contributor.authorHashemi, Farid
dc.contributor.authorZabolian, Amirhossein
dc.contributor.authorRaei, Mehdi
dc.contributor.authorHushmandi, Kiavash
dc.contributor.authorZarrabi, Ali
dc.contributor.authorVoelcker, Nicolas H.
dc.contributor.authorAref, Amir Reza
dc.contributor.authorHamblin, Michael R.
dc.contributor.authorVarma, Rajender S.
dc.contributor.authorSamarghandian, Saeed
dc.contributor.authorArostegi, I. J.
dc.contributor.authorAlzola, M.
dc.contributor.authorKumar, Alan Prem
dc.contributor.authorThakur, Vijay Kumar
dc.contributor.authorNabavi, Noushin
dc.contributor.authorMakvandi, Pooyan
dc.contributor.authorTay, Franklin R.
dc.contributor.authorOrive Arroyo, Gorka
dc.date.accessioned2021-12-10T12:25:47Z
dc.date.available2021-12-10T12:25:47Z
dc.date.issued2021-11-15
dc.identifier.citationCarbohydrate Polymers 272 : (2021) // Article ID 118491es_ES
dc.identifier.issn0144-8617
dc.identifier.issn1879-1344
dc.identifier.urihttp://hdl.handle.net/10810/54418
dc.description.abstract[EN]An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.es_ES
dc.description.sponsorshipGrant from the Ministry of Education -Singapore (MOE-T2EP30120-0016) supported APK. The National Research Foundation Singapore and the Singapore Ministry of Education under its Research Center of Excellence initiative to Cancer Science Institute of Singapore; National University of Singapore also supported APK. GO wish to thank the Spanish Ministry of Economy, Industry, and Competitiveness (SAF2016-76150-R and BFU2017-82421-P) and technical assistance from the ICTS NANBIOSIS (Drug Formulation Unit, U10) at the University of the Basque Country. Figs. 1 and 2 were drawn by Biorender (Biorender. com).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2016-76150-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/BFU2017-82421-Pes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectCD44es_ES
dc.subjectdoxorubicines_ES
dc.subjectdrug resistancees_ES
dc.subjectendocytosises_ES
dc.subjecthyaluronic acides_ES
dc.subjectnanodelivery systemes_ES
dc.subjecttheranostices_ES
dc.titleHyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppressiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2021 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S014486172100878X?via%3Dihubes_ES
dc.identifier.doi10.1016/j.carbpol.2021.118491
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail
Name:
license_rdf
Size:
914bytes
Format:
application/rdf+xml
View/Open
Thumbnail
Name:
1-s2.0-S014486172100878X-main.pdf
Size:
13.35Mb
Format:
PDF
Description:
Artículo
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2021 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Except where otherwise noted, this item's license is described as © 2021 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)